Literature DB >> 661863

Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction.

B M Alving, Y Hojima, J J Pisano, B L Mason, R E Buckingham, M M Mozen, J S Finlayson.   

Abstract

Thirteen lots of plasma protein fraction made by one manufacturer were implicated in 23 recent reports of hypotension in surgical patients. Four of these patients required resuscitation after rapid administration of the product in the postoperative period. All implicated lots had prekallikrein-activator activity but low levels of bradykinin and kallikrein. The prekallikrein activator was identified as Hageman-factor fragments by molecular weight (35,000 as estimated by gel chromatography), isoelectric point (4.2 to 4.4), and inhibition by antibody to Hageman factor. These data suggest that Hageman-factor fragments are potent hypotensive agents, presumably because they trigger the generation of bradykinin in recipients. Prekallikrein-activator activity, usually at levels lower than those in the initial 13 implicated lots, was frequently detected in plasma protein fraction made by other manufactures. Several of these lots were associated with additional reports of hypotension. Prekallikrein-activator activity rarely occurred in albumin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 661863     DOI: 10.1056/NEJM197807132990203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  14 in total

Review 1.  Anaphylactoid reactions to intravenous solutions used for volume substitution.

Authors:  J Ring
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

Review 2.  The use of plasma substitutes with special attention to their side effects.

Authors:  K F Messmer
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

Review 3.  Surface-mediated defense reactions. The plasma contact activation system.

Authors:  R W Colman
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

4.  The relationship between transfusion and hypoxemia in combat casualties.

Authors:  J A Collins; P M James; C E Bredenberg; R W Anderson; C A Heisterkamp; R L Simmons
Journal:  Ann Surg       Date:  1978-10       Impact factor: 12.969

5.  Vasodilator effects of the sodium acetate in pooled protein fraction.

Authors:  G N Olinger; P H Werner; L I Bonchek; L E Boerboom
Journal:  Ann Surg       Date:  1979-09       Impact factor: 12.969

6.  Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.

Authors:  A Overlack; K O Stumpe; C Ressel; R Kolloch; W Zywzok; F Krück
Journal:  Klin Wochenschr       Date:  1980-01-02

Review 7.  Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors.

Authors:  B Waeber; L Juillerat-Jeanneret; J F Aubert; M Schapira; J Nussberger; H R Brunner
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

Review 9.  Use of plasma volume expanders in myocardial revascularisation.

Authors:  J H Lacy; C B Wright
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

10.  Protection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.

Authors:  M Schapira; M A Ramus; B Waeber; H R Brunner; S Jallat; D Carvallo; C Roitsch; M Courtney
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.